Progress in Boehringer Ingelheim collaboration triggers milestone payment

Collaboration continues to investigate novel ion channel target with potential in multiple disease areas related to lysosomal dysfunction

Stevenage, UK – 03 September 2024 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious nervous system disorders, including neurodegenerative diseases, epilepsy, schizophrenia and Fragile X Syndrome, today announced that a key financial milestone has been achieved in the ongoing collaboration with Boehringer Ingelheim. This collaboration had been communicated in a press release in March 2021, see link here

Autifony and Boehringer Ingelheim’s Research Beyond Borders (BI RBB) team will continue to investigate a novel ion channel target involved in the function of cellular lysosomes to discover and develop first-in-class modulators of these channels which have the potential to treat a range of indications linked to lysosomal dysfunction.
Financial details of the milestone are not disclosed. Autifony is set to benefit from ongoing research funding as well as further success-related milestones and other downstream payments as the programme continues to progress.
Dr Charles Large, Chief Executive Officer, of Autifony Therapeutics commented: “Reaching this milestone is a fantastic achievement and recognises the significant progress made by the team to date. In addition it is testament to the excellent collaboration and working relationship that continues to build between BI RBB, the wider BI team, and Autifony. We look forward to continuing to work together to take this programme forward with the mutual goal of developing ground-breaking treatments for patients in areas of significant unmet medical need.”

About Autifony Therapeutics Ltd
Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK, which retains equity in the company. The Company is focused on the development of high value, novel medicines to treat a growing humber of Central Nerous System and other diseases with high unmet medical need. It is funded by SV Health Investors, IP Group, Pfizer Ventures, International Biotechnology Trust PLC, and UCL Business plc.

For more information please visit www.autifony.com
For more information, please contact:
Autifony Therapeutics Limited
Dr Charles Large, CEO
E: [email protected]